230 related articles for article (PubMed ID: 22561544)
21. Antitumor platinum(II) complexes of N-monoalkyl 1R,2R-diamino-cyclohexanes with 3-(nitrooxy)cyclobutane-1,1-dicarboxylate as a leaving group.
Zhao J; Gou S; Xu G; Cheng L
Eur J Med Chem; 2014 Oct; 85():408-17. PubMed ID: 25108080
[TBL] [Abstract][Full Text] [Related]
22. Toward overcoming cisplatin resistance via sterically hindered platinum(II) complexes.
Yu H; Gou S; Wang Z; Chen F; Fang L
Eur J Med Chem; 2016 May; 114():141-52. PubMed ID: 26974381
[TBL] [Abstract][Full Text] [Related]
23. Cisplatinum and transplatinum complexes with benzyliminoether ligands; synthesis, characterization, structure-activity relationships, and in vitro and in vivo antitumor efficacy.
Sbovata SM; Bettio F; Mozzon M; Bertani R; Venzo A; Benetollo F; Michelin RA; Gandin V; Marzano C
J Med Chem; 2007 Sep; 50(19):4775-84. PubMed ID: 17713897
[TBL] [Abstract][Full Text] [Related]
24. Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes.
Khokhar AR; al-Baker S; Shamsuddin S; Siddik ZH
J Med Chem; 1997 Jan; 40(1):112-6. PubMed ID: 9016335
[TBL] [Abstract][Full Text] [Related]
25. Platinum(II) oxalato complexes with adenine-based carrier ligands showing significant in vitro antitumor activity.
Starha P; Trávnícek Z; Popa I
J Inorg Biochem; 2010 Jun; 104(6):639-47. PubMed ID: 20304500
[TBL] [Abstract][Full Text] [Related]
26. [Synthesis and antitumor activities of triazacyclodecane and its platinum (II) complex].
Zhou SS; Zhang QY; Qin K; Lu CH; Xie FX
Yao Xue Xue Bao; 2008 May; 43(5):490-4. PubMed ID: 18717336
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and structure-activity relationship of novel antitumoral platinum xanthate complexes.
Friebolin W; Schilling G; Zöller M; Amtmann E
J Med Chem; 2004 Apr; 47(9):2256-63. PubMed ID: 15084124
[TBL] [Abstract][Full Text] [Related]
28. Preparation of antitumor oxaliplatin/cisplatin docking dinuclear platinum complex.
Noji M; Kizu R; Takeda Y; Akiyama N; Yoshizaki I; Eriguchi M; Kidani Y
Biomed Pharmacother; 2005 Jun; 59(5):224-9. PubMed ID: 15919175
[TBL] [Abstract][Full Text] [Related]
29. Platinum (II) complexes with stereochemically-defined thiepane dioxide diamine ligands as anticancer drugs.
Cerè V; Grossi L; Munari D; Pollicino S; Martelli L; Martelli M
Anticancer Res; 2006; 26(3A):1815-9. PubMed ID: 16827112
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, cytotoxicity, and apoptosis induction study of antitumor dinuclear platinum(II) complexes.
Xu G; Gou S; Gao C
Arch Pharm (Weinheim); 2013 Apr; 346(4):308-13. PubMed ID: 23447402
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxicity of platinum(IV) and platinum(II) complexes containing 1R,2R-cyclohexanediamine as a ligand.
Yamashita T; Hirose J; Noji M; Saito R; Tomida H; Kidani Y
Biol Pharm Bull; 1993 Oct; 16(10):1014-8. PubMed ID: 8287030
[TBL] [Abstract][Full Text] [Related]
33. New platinum(II) complexes containing both an O,O'-chelated acetylacetonate ligand and a sulfur ligand in the platinum coordination sphere induce apoptosis in HeLa cervical carcinoma cells.
Muscella A; Calabriso N; De Pascali SA; Urso L; Ciccarese A; Fanizzi FP; Migoni D; Marsigliante S
Biochem Pharmacol; 2007 Jun; 74(1):28-40. PubMed ID: 17481588
[TBL] [Abstract][Full Text] [Related]
34. Asymmetrically substituted ethylenediamine platinum(II) complexes as antitumor agents: synthesis and structure-activity relationships.
Mailliet P; Segal-Bendirdjian E; Kozelka J; Barreau M; Baudoin B; Bissery MC; Gontier S; Laoui A; Lavelle F; Le Pecq JB
Anticancer Drug Des; 1995 Jan; 10(1):51-73. PubMed ID: 7695813
[TBL] [Abstract][Full Text] [Related]
35. Sterically hindered complexes of platinum(II) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-cytosine has a spectrum of activity different from cisplatin and is able of overcoming acquired cisplatin resistance.
Margiotta N; Natile G; Capitelli F; Fanizzi FP; Boccarelli A; De Rinaldis P; Giordano D; Coluccia M
J Inorg Biochem; 2006 Nov; 100(11):1849-57. PubMed ID: 16959321
[TBL] [Abstract][Full Text] [Related]
36. Enantiomerically pure [1, 2-diamino-1-(4-fluorophenyl)butane]platinum(II) complexes: synthesis and antitumor activity against MCF-7 and MDA-MB 231 breast cancer and LnCaP/FGC prostate cancer cell lines.
Dullin A; Dufrasne F; Gelbcke M; Gust R
Arch Pharm (Weinheim); 2004 Dec; 337(12):654-67. PubMed ID: 15597399
[TBL] [Abstract][Full Text] [Related]
37. cis-[Pt(II) (1R,2R-DACH)(3-acetoxy-1,1-cyclobutanedicarboxylato)], a water-soluble, oxalate-free and stable analogue of oxaliplatin: synthesis, characterization, and biological evaluations.
Liu W; Ye Q; Jiang J; Lou L; Xu Y; Xie C; Xie M
ChemMedChem; 2013 Sep; 8(9):1465-7. PubMed ID: 23825063
[No Abstract] [Full Text] [Related]
38. Poly (γ, L-glutamic acid)-cisplatin bioconjugate exhibits potent antitumor activity with low toxicity: a comparative study with clinically used platinum derivatives.
Feng Z; Lai Y; Ye H; Huang J; Xi XG; Wu Z
Cancer Sci; 2010 Nov; 101(11):2476-82. PubMed ID: 20813014
[TBL] [Abstract][Full Text] [Related]
39. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Sun J; Tan CJ; Dai Z
Expert Opin Investig Drugs; 2009 Nov; 18(11):1595-604. PubMed ID: 19780708
[TBL] [Abstract][Full Text] [Related]
40. Effect of the diamine nonleaving group in platinum-acridinylthiourea conjugates on DNA damage and cytotoxicity.
Guddneppanavar R; Choudhury JR; Kheradi AR; Steen BD; Saluta G; Kucera GL; Day CS; Bierbach U
J Med Chem; 2007 May; 50(9):2259-63. PubMed ID: 17408248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
